|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, these findings suggest that OLFM4 plays an important tumor-suppressor role in prostate cancer progression and might be useful as a novel candidate biomarker for prostate cancer.
|
31241767 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, the expression levels of OLFM4 in 59 cases of early‑stage tongue SCC were analyzed using immunohistochemistry to examine protein expression corresponding to the histopathological definition of tumors and to evaluate prognosis.
|
31432153 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, our results confirm OLFM4 as a tumor suppressor that inhibits cervical cancer metastasis by regulating mTOR signal pathway.
|
30764901 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immuno-proteomic discovery of tumor tissue autoantigens identifies olfactomedin 4, CD11b, and integrin alpha-2 as markers of colorectal cancer with liver metastases.
|
28669815 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, plasma OLFM4 level may be considered as a biomarker for diagnosis and prognosis of breast cancer for cases where there are difficulties in obtaining tumor tissue samples.
|
29344255 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Low expression of OLFM4 was also associated with high tumor FIGO stage and poor tumor differentiation.
|
26871282 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Together, our findings indicate that OLFM4 is a novel candidate tumor-suppressor gene for chromosome 13q and may shed new light on strategies that could be used for the diagnosis, prognosis, and treatment of prostate cancer patients.
|
24070418 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Interestingly, similar to stem cells in normal tissues, Lgr5(+) cells were often restricted to the base of the tumor glands, and such Lgr5(+) restriction was associated with high levels of intestinal stem cell markers such as EPHB2, OLFM4, and ASCL2.
|
24340024 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The roles of OLFM4 in tumor growth and metastasis and how it functions in these processes remain elusive.
|
23161172 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this minireview, we mainly focus on the OLFM4 expression and its biological significances in tumor differentiation and progression as well as the contributions of OLFM4 to tumorigenesis.
|
21067260 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
GW112 expression correlated with advanced tumor stage.
|
19261089 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The association of hGC-1 expression pattern with patient differentiation grade, tumor stage, metastasis, and survival were examined.
|
18281536 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Enhanced hGC-1 expression was more frequently seen in intestinal-type adenocarcinoma, whereas loss of expression tended to occur in the diffuse type. hGC-1 was highly expressed in well or moderately differentiated cancers and was remarkably reduced or lost in poorly differentiated or undifferentiated tumours.
|
17650212 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MIA and GW112 were overexpressed in 10 (25%) and 22 (55%) of 40 GC samples, and the overexpression of these two genes was associated with tumor stage, respectively.
|
16210872 |
2005 |